ReviewFrontiers in neuroscience2020
Sex-Specific Pharmacotherapy for Migraine: A Narrative Review.
Review in Frontiers in neuroscience, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Gender bias in clinical trials of biological agents for migraine: A systematic review.PloS one · 2023Pooled it
- Impact of age and sex on the efficacy of fremanezumab in patients with difficult-to-treat migraine: results of the randomized, placebo-controlled, phase 3b FOCUS study.The journal of headache and pain · 2021Trial
- Migraine and menopause as converging factors in brain vulnerability: a hypothesis-driven perspective.The journal of headache and pain · 2026Review
- [Influence of Clinical and Demographic Variables on the Characteristics of Migraine Attacks].Revista de neurologia · 2025Observational
- The association between social factors and migraine or severe headache in men: a secondary analysis of national population-based studies with machine learning models.The journal of headache and pain · 2025Article
- Migraine in men.The journal of headache and pain · 2025Review
- Sex differences in expression of CGRP family of receptors and ligands in the rat trigeminal system.The journal of headache and pain · 2024Article
- Migraine treatment: quo vadis? Real-world data study (2015-2022) in Spain.BMC neurology · 2024Article
- Central generators of migraine and autonomic cephalalgias as targets for personalized pain management: Translational links.European journal of pain (London, England) · 2023Review
- Review
- Headache, eating disorders, PTSD, and comorbidity: implications for assessment and treatment.Eating and weight disorders : EWD · 2022Article
- B vitamins and their combination could reduce migraine headaches: A randomized double-blind controlled trial.Current journal of neurology · 2022Article
- Rimegepant for the treatment of migraine.Health psychology research · 2022Article
- Unpredictable Sound Stress Model Causes Migraine-Like Behaviors in Mice With Sexual Dimorphism.Frontiers in pharmacology · 2022Article
- Neurogenic Inflammation: The Participant in Migraine and Recent Advancements in Translational Research.Biomedicines · 2021Review
- A link between migraine and prolactin: the way forward.Future science OA · 2021Review
- Hormonal influences in migraine - interactions of oestrogen, oxytocin and CGRP.Nature reviews. Neurology · 2021Review
- Review
- Clinical Manifestations of Overactive Bladder With Migraine as a Comorbidity: A Prospective Cross-Sectional Study.International neurourology journal · 2020Article
- Roles of mast cells and their interactions with the trigeminal nerve in migraine headache.Molecular painReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Migraine is a common neurological disorder characterized by recurrent headache episodes that accompany sensory-motor disturbances, such as higher sensitivity to touch and light, extremity heaviness or weakness, and speech or language disabilities. Worldwide, migraine is one of the top 10 causes of disability and hence poses a huge economic burden to society. On average, migraine occurs in 12% of population but its occurrence is sexually dimorphic, as it is two to three times more prevalent in women than in men. This female to male ratio of migraine prevalence is age- and sex hormone-dependent. Advancements in understanding migraine pathogenesis have also revealed an association with both genetics and epigenetics. The severity of migraine, in terms of its attack duration, headache intensity, frequency, and occurrence of migraine-associated symptoms, has generally been reported to be greater in women. Sex differences in migraine disability and comorbidities, such as psychiatric disorders, have also been noted in some population-based studies. However, research on sex-related differences in response to migraine treatments is relatively scarce. Although a general observation is that women consume more medication than men for migraine treatment, strategies for the use of abortive and preventive medications for migraine are generally similar in both sexes. This narrative review summarizes available findings on sexually distinct responses to abortive and prophylactic pharmacotherapy of migraine. Basic experimental data and clinical findings will be presented, and potential mechanisms underlying sex-based responses will be discussed to highlight the importance and value of sex-based treatment in migraine research and practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.